$CAPR News
Last published 1d ago
- 1d agoCAPRCAPRICOR THERAPEUTICS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoCAPRCapricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.
- 2d agoCAPRCapricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric CardiologyGlobeNewswireSAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today
- 2d agoCAPRCapricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric CardiologyGlobeNewswireSAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the abstract presenting cardiac results from the Company’s HOPE-3 Phase 3 trial of Deramiocel in Duchenne muscular dystrophy (DMD) received the Outstanding Research Award in ...
- 1w agoCAPRCapricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10GlobeNewswireSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today
- 1mo agoCAPRCapricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society CongressGlobeNewswire– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17,
- 1mo agoCAPRKirby McInerney LLP Alerts Investors Who Acquired Capricor Therapeutics, Inc. CAPR Securities Between December 17, 2025 and July 26, 2026 of Pending LawsuitGlobeNewswireNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR) investors of the September 28, 2026 deadline to seek the
- 2mo agoCAPRCapricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLAGlobeNewswire– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication – SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Capricor
- 2mo agoCAPRKaos Capital Calls on Capricor (NASDAQ: CAPR) ShareholdersPR NewswireKaos Capital Ltd. ("Kaos Capital," "we," or "us"), a significant and growing shareholder of Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("Capricor" or ...
- 2mo agoCAPRCAPR INVESTOR REMINDER: Capricor Therapeutics, Inc. Investors Have Until September 28, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff RoleBusiness WireIf you have suffered a loss on your Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at
- 2mo agoNTHIMDXHCAPRONFOThese Biotech Breakouts and Squeeze Setups Could Be Just Getting StartedGlobeNewswireDENVER, Aug. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s stock market coverage illustrates two very different kinds of momentum. NeOnc (NASDAQ:NTHI), MDxHealth (NASDAQ:MDXH), and Capricor Therapeutics
- 3mo agoCAPRCapricor Therapeutics Second Quarter 2026 Conference Call - CAPRICOR THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen, and welcome to the Capricorn Therapeutics Second Quarter 2026 Conference Call. If at any time during this call you require immediate assistance, please press star zero for the operat
- 3mo agoCAPRCapricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireDeramiocel Biologics License Application (BLA) under active FDA reviewHOPE-3 Phase 3 results published in The Lancet; primary endpoint of upper limb function achieved at p=0.029Cash, cash equivalents and marketable
- 3mo agoCAPRCAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock DropPR NewswireCapricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock
- 3mo agoCAPRCapricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13GlobeNewswireSAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today
- 3mo agoCAPRLowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities LawsGlobeNewswireNEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ:CAPR) ("Capricor"
- 3mo agoCAPRCapricor Therapeutics Provides Update on FDA Advisory Committee Meeting for DeramiocelGlobeNewswireSAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S.
- 3mo agoCAPRThe Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular DystrophyGlobeNewswire--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint,
- 3mo agoCAPRBREAKING: Capricor Therapeutics Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Learn MoreGlobeNewswireBOSTON, July 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Capricor Therapeutics (NASDAQ:CAPR) for potential securities law violations. Investors who have lost money in their Capricor Therapeutics
- 3mo agoCAPRCapricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for DeramiocelGlobeNewswireSAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided an update ahead
- 4mo agoCAPRCapricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular DystrophyGlobeNewswire–Advisory Committee meeting scheduled for July 29, 2026––Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor
- 4mo agoCAPRCapricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual ConferenceGlobeNewswireDeramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE studyPUL 2.0 year-over-year decline attenuated to approximately 1 pointFindings to be presented alongside previously
- 5mo agoCAPRCapricor Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior
- 6mo agoCAPRCapricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireDeramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soonHOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all
- 6mo agoCAPRCapricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12GlobeNewswire– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and
- 6mo agoCAPRCapricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual MeetingGlobeNewswireSAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the
- 8mo agoCAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireDeramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint
- 8mo agoCAPRCapricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular DystrophyGlobeNewswireReduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022)Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017)Global Statistical Test (GST) composite
- 8mo agoCAPRCapricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLAGlobeNewswireDeramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, including achievement
- 8mo agoCAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12GlobeNewswire– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and
- 8mo agoCAPRCapricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific ConferenceGlobeNewswireLate-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophyHOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in
- 9mo agoCAPRCapricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline DataGlobeNewswireFDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO, Jan. 20, 2026 (GLOBE
- 11mo agoCAPRCapricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular DystrophyGlobeNewswire– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company developing transformative cell and
- 11mo agoCAPRCapricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular DystrophyGlobeNewswirePivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04,
- 11mo agoCAPRCapricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025GlobeNewswire--Findings support the versatility of Capricor's exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) --
- 1y agoCAPRCapricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireTopline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3
- 1y agoCAPRKuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ:CAPR) breached their
- 1y agoCAPRCapricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, DeramiocelGlobeNewswire–Publication highlights Deramiocel's anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, 2025 (GLOBE
- 1y agoCAPRCapricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10GlobeNewswireSAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today
- 1y agoCAPRKuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ:...
- 1y agoCAPRCapricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A MeetingGlobeNewswireFDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resub
- 1y agoCAPRShareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPRGlobeNewswireNEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ:CAPR). Shareholders who purchased shares of CAPR during the
- 1y agoCAPRCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPRPR NewswireThe Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of...
- 1y agoCAPRINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("Capricor" or...
- 1y agoCAPRCapricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for DeramiocelGlobeNewswireSAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement
- 1y agoCAPRINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("Capricor" or...
- 1y agoCAPRSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Capricor To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoCAPRCapricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CAPRPR NewswireThe Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of...
- 1y agoCAPRSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("Capricor" or...
- 1y agoCAPRCAPR Investors Have the Opportunity to Lead the Capricor Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLPGlobeNewswireIf You Suffered Losses Exceeding $50,000 in Capricor between October 9, 2024 and July 10, 2025 Securities Litigation Partner James (Josh) Wilson Encourages you to contact him directly at 877-247-4292 or 212-983-9330